Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841359 | 1.00 | KMT2A (0.46) | KMT2ASMN1; SMN2CES2CES1ITGB3 | |
| SCHEMBL7951522 | 1.00 | KMT2A (0.46) | KMT2ASMN1; SMN2CES2CES1ITGB3 | |
| Hydrochloric Acid SCHEMBL12497510 | 0.98 | KMT2A (0.44) | KMT2ASMN1; SMN2CES2CES1ITGB3 | |
| SCHEMBL28205017 | 0.85 | KMT2A (0.43) | KMT2ASMN1; SMN2CYP2C9MEN1CYP2D6 | |
| SCHEMBL14580270 | 0.85 | AKR1C3 (0.47) | KMT2ASMN1; SMN2MEN1LMNAFFAR1 | |
| SCHEMBL19283456 | 0.83 | KMT2A (0.42) | KMT2ASMN1; SMN2CYP2C9MEN1CYP2D6 | |
| SCHEMBL20546151 | 0.83 | KMT2A (0.48) | KMT2ASMN1; SMN2FFAR1DPP4 | |
| SCHEMBL20546154 | 0.83 | KMT2A (0.48) | KMT2ASMN1; SMN2FFAR1DPP4 | |
| SCHEMBL12497499 | 0.82 | FFAR1 (0.53) | KMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL7809416 | 0.81 | GABBR2 (0.47) | KMT2ACES2CES1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702157-A1 | ACYL-TRNA SYNTHETASES | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | claimed |
| WO-2024223922-A1 | ACYL-tRNA SYNTHETASES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-10-31 | — | — | WO | claimed |
| EP-4702157-A1 | ACYL-TRNA SYNTHETASES | United Kingdom Research and Innovation (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024223922-A1 | ACYL-tRNA SYNTHETASES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-10-31 | — | — | WO | disclosed |
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | ALMAC DISCOVERY LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | disclosed |
| US-9663516-B2 | Bicyclic-pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663516-B2 | Bicyclic-pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-06-23 | — | — | US | disclosed |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | USP19, USP18, UBE2I | KMT2A 1973/4885SMN1; SMN2 2749/4885CES2 877/4885 |
| US-20160176868-A1 | BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | TNNI3, NME4, TNNT2 | KMT2A 3818/4885SMN1; SMN2 2201/4885CES2 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.